TRADE NEWS: Agilent Technologies Collaborating with Florida International
University to Identify and Characterize Designer Drugs
SANTA CLARA, Calif. -- February 25, 2013
Agilent Technologies Inc. (NYSE: A) today announced it is collaborating with
Florida International University’s department of chemistry and biochemistry
and its International Forensics Research Institute to further advance the
identification and characterization of so-called designer drugs.
This work is currently focused on developing and validating new methods for
rapid forensic screening and analysis based on advanced chromatography and
mass-spectrometry systems such as LC-QQQ-MS/MS, LC-QTOF-MS, GC/MS and
GC/MS/MS. The new methods will expand the capabilities of traditional
drug-screening procedures involving immunoassays.
“Since routine immunoassay drug-screening methods are unable to detect most of
the hundreds of individual designer drugs that have been identified, we are
working with Agilent to develop advanced analytical methods to screen and
confirm the presence of such drugs in both ante- and post-mortem specimens,”
said Dr. Anthony DeCaprio, associate professor and director of the Forensic &
Analytical Toxicology facility at Florida International University’s
International Forensic Research Institute. “Recently, we validated a method
for the detection and quantification of 32 designer drugs in serum, including
24 phenethylamines, four piperazines, and four tryptamines. In collaboration
with Agilent, we will continue to expand our tandem mass-spectral library to
approximately 300 designer drugs.”
Dr. DeCaprio will present data of interest to forensic scientists and
toxicologists in an e-seminar on Tuesday, Feb. 26, as part of a six-seminar
series (live and on-demand) at ForensicEd.org. To learn more about the Florida
International University designer drug program, visit “Targeted LC-QQQ MS
Screening of Cathinone Derivitaves and Other Designer Drugs in Serum.”
Designer drugs are novel analogs or derivatives of existing illicit drug
compounds that are synthesized to circumvent existing laws and to produce
similar effects as illegal recreational drugs. Major classes of designer drugs
include phenethylamines, cathinones, tryptamines, piperazines, and synthetic
cannabinoids. For years, black-market laboratories could produce and
distribute these drugs with little to no threat of prosecution, until last
summer when U.S. President Obama signed a bill into law designating certain
chemicals found in designer drugs as illegal substances. Today, as with other
illicit drugs already covered under federal law, selling and distributing many
specific designer drugs is now prohibited in the United States.
“It is our goal to provide private, academic and government institutions with
sophisticated technology and screening methods that will quickly and
accurately identify these substances so that laws enacted to restrict their
use can be readily enforced,” said Tom Gluodenis, Agilent’s global marketing
manager of Forensics and Toxicology. “We look forward continuing our work with
Dr. DeCaprio and his team at Florida International University, and commend
them on their ambitious efforts in this important area of research.”
About Agilent in Forensics
Agilent is committed to helping protect public health and safety through the
development of groundbreaking measurement and analysis technologies for a
variety of forensic areas, including criminalistics, doping control,
toxicology and DNA testing. The company is a leading provider of advanced
instrumentation and drug-testing methods, and a partner to prominent
universities, law enforcement and government organizations around the world.
Agilent was the first company to develop a compendium for testing synthetic
cannabinoids. For more information, visit Agilent’s Forensics & Toxicology
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news
is available at www.agilent.com/go/news.
Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
Press spacebar to pause and continue. Press esc to stop.